These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 19765437)

  • 1. Could prophylactic monoclonal antibody improve kidney graft survival?
    Pourmand G; Saraji A; Salem S; Mehrsai A; Nikoobakht MR; Taherimahmoudi M; Rezaeidanesh M; Asadpour A
    Transplant Proc; 2009 Sep; 41(7):2794-6. PubMed ID: 19765437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
    Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
    Abou-Ayache R; Büchler M; Lepogamp P; Westeel PF; Le Meur Y; Etienne I; Lobbedez T; Toupance O; Caillard S; Goujon JM; Bergougnoux L; Touchard G
    Nephrol Dial Transplant; 2008 Jun; 23(6):2024-32. PubMed ID: 18199693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors.
    Sánchez-Fructuoso AI; Prats D; Marques M; Ridao N; Conesa J; García Mena M; Torrente J; Barrientos A
    Transplant Proc; 2003 Aug; 35(5):1689-90. PubMed ID: 12962759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
    Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
    Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF
    Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function.
    Bumgardner GL; Ramos E; Lin A; Vincenti F;
    Transplantation; 2001 Aug; 72(4):642-7. PubMed ID: 11544424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.
    Kandus A; Grego K; Bren AF
    Ther Apher Dial; 2005 Jun; 9(3):262-4. PubMed ID: 15967003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G; Walsh G; Deshpande P; Koffman G
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation.
    Fangmann J; Arns W; Marti HP; Hauss J; Ketteler M; Beckurts T; Boesmueller C; Pohanka E; Martin PY; Gerhardt M; Farese S; Neumayer HH; Floege J; Gurr C; Budde K;
    Nephrol Dial Transplant; 2010 Jan; 25(1):283-92. PubMed ID: 19773417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
    Sarwal MM; Vidhun JR; Alexander SR; Satterwhite T; Millan M; Salvatierra O
    Transplantation; 2003 Nov; 76(9):1331-9. PubMed ID: 14627912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclizumab to prevent rejection after cardiac transplantation.
    Hershberger RE; Starling RC; Eisen HJ; Bergh CH; Kormos RL; Love RB; Van Bakel A; Gordon RD; Popat R; Cockey L; Mamelok RD
    N Engl J Med; 2005 Jun; 352(26):2705-13. PubMed ID: 15987919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-interleukin 2-receptor antibodies: a comparative study with polyclonal antibodies in kidney transplantation: preliminary results.
    Martins L; Henriques AC; Dias L; Sarmento AM; Pereira MC; Guimarães S
    Transplant Proc; 2000 Dec; 32(8):2623-5. PubMed ID: 11134730
    [No Abstract]   [Full Text] [Related]  

  • 15. Low rate of acute rejection and cytomegalovirus infection in kidney transplant recipients with basiliximab.
    Folkmane I; Bicans J; Amerika D; Chapenko S; Murovska M; Rosentals R
    Transplant Proc; 2001; 33(7-8):3209-10. PubMed ID: 11750377
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
    Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J
    Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
    [No Abstract]   [Full Text] [Related]  

  • 17. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-2 receptor blockers in liver transplantation: initial experience with daclizumab in Chile.
    Innocenti F; Humeres R; Zamboni M; Sanhueza E; Zapata R; Hepp J; Rius M
    Transplant Proc; 2003 Nov; 35(7):2520-1. PubMed ID: 14612001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients.
    Ravichandran P; Natrajan T; Jaganathan R
    Int Immunopharmacol; 2006 Dec; 6(13-14):1973-6. PubMed ID: 17161350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids.
    Tran HTB; Acharya MK; McKay DB; Sayegh MH; Carpenter CB; Auchincloss H; Kirkman RL; Milford EL
    J Am Soc Nephrol; 2000 Oct; 11(10):1903-1909. PubMed ID: 11004222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.